Healthcare
HUTCHMED (China) Limited(HCM)
Live Price
Offline$10.28
+1.58% today
Window Change
-22.31%
Window
May 4, 2026 โ Jun 24, 2026
- Market Cap
- $2.32B
- Revenue Growth
- -12.7%
- EPS Growth
- +1101.8%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 36 bars ยท May 4, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
HUTCHMED (China) Limited (HCM) is a Healthcare stock with a market cap of $2.32B and listed on NASDAQ. The stock last traded around $10.28 and down 22.3% across the available one-year price window (May 4, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of -12.7%, EPS growth of +1101.8%, a dividend yield of 0.0%. What stands out right now is revenue -12.7%, EPS +1101.8%, free cash flow -353.2% with operating margin -2.6% and ROIC -0.7%. Valuation is more restrained than many high-expectation growth names at P/E 5.1 and price/sales 5.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HCM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-12.7% vs +7.6% peer median
Operating Margin
Below sector median
-2.6% vs +19.4% peer median
P/E
Below sector median
5.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 5, 2026 with revenue below estimates by -6.7%.
The operating picture looks softer than before
Revenue is at -12.7% and EPS is at +1101.8%, with operating margin around -2.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 3, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
HCM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HCM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HCM Max Drawdown
-25.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HCM and SPY.
Company Overview
HUTCHMED (China) Limited
NASDAQ Global Select
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
- Leadership
- Chig Fung Cheng
- IPO Date
- Mar 16, 2016
- Employees
- 1.8k
- Street Address
- Cheung Kong Center
- Mailing
- Hong Kong
- Region
- Hong Kong, HK
- Reporting Currency
- USD
- Investor Line
- 852 2128 1188
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 5.1
- EV/EBITDA
- โ
- Price/Sales
- 5.3
- Price/Book
- 1.9
Growth
- Revenue
- -12.7%
- EPS
- +1101.8%
- Free Cash Flow
- -353.2%
Profitability
- Gross Margin
- 18.6%
- Operating Margin
- -2.6%
- Net Margin
- 104.8%
- ROE
- 41.4%
- ROIC
- -0.7%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 4.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.